Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.
1. A method of treating ulcerative colitis (UC) in a human subject, comprising:
obtaining a sample from the human subject with UC;
contacting the sample with an oligonucleotide probe specific to an “A” allele at nucleotide 465 of SEQ ID NO:1, an oligonucleotide probe specific to an “A” allele at nucleotide 301 of SEQ ID NO:2, an oligonucleotide probe specific to a “C” allele at nucleotide 301 of SEQ ID NO:3, an oligonucleotide probe specific to an “A” allele at nucleotide 3412 of SEQ ID NO:4, an oligonucleotide probe specific to a variant allele at any one of nucleotides 4505-4604 of SEQ ID NO:4, an oligonucleotide probe specific to a “G” allele at nucleotide 364 of SEQ ID NO:5, an oligonucleotide probe specific to an “A” allele at nucleotide 251 of SEQ ID NO:6, an oligonucleotide probe specific to a “G” allele at nucleotide 239 of SEQ ID NO:7, an oligonucleotide probe specific to an “A” allele at nucleotide 250 of SEQ ID NO:8, an oligonucleotide probe specific to a “G” allele at nucleotide 501 of SEQ ID NO:9, an oligonucleotide probe specific to a “G” allele at nucleotide 301 of SEQ ID NO:10, an oligonucleotide probe specific to an “A” allele at nucleotide 501 of SEQ ID NO:11, an oligonucleotide probe specific to an “A” allele at nucleotide 501 of SEQ ID NO:12, an oligonucleotide probe specific to a “G” allele at nucleotide 201 of SEQ ID NO:13, an oligonucleotide probe specific to an “A” allele at nucleotide 244 of SEQ ID NO:14, an oligonucleotide probe specific to a “G” allele at nucleotide 501 of SEQ ID NO:15, an oligonucleotide probe specific to a “G” allele at nucleotide 195 of SEQ ID NO:16, an oligonucleotide probe specific to a “G” allele at nucleotide 101 of SEQ ID NO:17, an oligonucleotide probe specific to an “A” allele at nucleotide 582 of SEQ ID NO:18, an oligonucleotide probe specific to an “A” allele at nucleotide 301 of SEQ ID NO:19, an oligonucleotide probe specific to a “G” allele at nucleotide 324 of SEQ ID NO:20, an oligonucleotide probe specific to an “A” allele at nucleotide 301 of SEQ ID NO:21, an oligonucleotide probe specific to a “G” allele at nucleotide 1394 of SEQ ID NO:22, an oligonucleotide probe specific to an “A” allele at nucleotide 251 of SEQ ID NO:23, an oligonucleotide probe specific to an “A” allele at nucleotide 201 of SEQ ID NO:24, an oligonucleotide probe specific to an “A” allele at nucleotide 301 of SEQ ID NO:25, an oligonucleotide probe specific to a “G” allele at nucleotide 301 of SEQ ID NO:26, an oligonucleotide probe specific to a “G” allele at nucleotide 1124 of SEQ ID NO:27, an oligonucleotide probe specific to an “A” allele at nucleotide 501 of SEQ ID NO:28, an oligonucleotide probe specific to a “G” allele at nucleotide 2000 of SEQ ID NO:29, an oligonucleotide probe specific to a “G” allele at nucleotide 351 of SEQ ID NO:30, an oligonucleotide probe specific to an “A” allele at nucleotide 301 of SEQ ID NO:31, an oligonucleotide probe specific to a “G” allele at nucleotide 380 of SEQ ID NO:32, an oligonucleotide probe specific to an “A” allele at nucleotide 201 of SEQ ID NO:33, an oligonucleotide probe specific to a “G” allele at nucleotide 1158 of SEQ ID NO:34, an oligonucleotide probe specific to a “G” allele at nucleotide 371 of SEQ ID NO:35, an oligonucleotide probe specific to a “C” allele at nucleotide 201 of SEQ ID NO:36, an oligonucleotide probe specific to an “A” allele at nucleotide 501 of SEQ ID NO:37, an oligonucleotide probe specific to a “G” allele at nucleotide 50 of SEQ ID NO:38, an oligonucleotide probe specific to an “A” allele at nucleotide 201 of SEQ ID NO:39, an oligonucleotide probe specific to an “A” allele at nucleotide 501 of SEQ ID NO:40, an oligonucleotide probe specific to a “C” allele at nucleotide 201 of SEQ ID NO:41, an oligonucleotide probe specific to a “G” allele at nucleotide 401 of SEQ ID NO:42, an oligonucleotide probe specific to a “C” allele at nucleotide 401 of SEQ ID NO:43, an oligonucleotide probe specific to an “A” allele at nucleotide 101 of SEQ ID NO:44, an oligonucleotide probe specific to a “G” allele at nucleotide 307 of SEQ ID NO:45, and an oligonucleotide probe specific to an “A” allele at nucleotide 251 of SEQ ID NO:46, to form allele-specific hybridization complex(es) between the oligonucleotide probes and target alleles in the sample;
assessing the binding between the oligonucleotide probes and the target alleles thereof, by detecting the allele-specific hybridization complexes;
prognosing the human subject with UC with an earlier progression to colectomy based on the allele-specific hybridization complex(es) detected; and
treating the human subject with UC prognosed with an earlier progression to colectomy by performing a surgical procedure comprising colectomy.
2. The method of claim 1 , wherein UC comprises MR-UC.
3. The method of claim 1 , wherein the subject treated has a higher incidence of MR-UC.
4. The method of claim 1 , wherein colectomy is performed within about 10 months from UC prognosis.
5. The method of claim 1 , wherein colectomy is performed within 10 to 40 months from UC prognosis.
6. The method of claim 1 , wherein colectomy is performed within 40 to 72 months from UC prognosis.